NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
20.19
-1.06 (-4.99%)
At close: Oct 13, 2026, 4:00 PM EDT
20.20
+0.01 (0.05%)
After-hours: Oct 13, 2026, 7:30 PM EDT
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $3.70M in the quarter ending June 30, 2026, a decrease of -80.67%. This brings the company's revenue in the last twelve months to $7.12M, down -88.87% year-over-year. In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%. That makes NewAmsterdam Pharma Company the 38,707th largest company in the world by revenue and 5,104th in the United States.
Revenue (ttm)
$7.12M
Revenue Growth
-88.87%
P/S Ratio
338.92
Revenue / Employee
$71,210
Employees
100
Market Cap
2.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.50M | -23.06M | -50.61% |
| Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
| Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
| Dec 31, 2022 | 102.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| Nurix Therapeutics | 701.94M |
| ADMA Biologics | 512.28M |
| Zai Lab | 449.61M |
| Aurinia Pharmaceuticals | 311.51M |
| Beam Therapeutics | 156.04M |
| Precigen | 85.72M |
| Celldex Therapeutics | 158.00K |
NAMS News
- 8 days ago - NewAmsterdam Pharma price target lowered to $42 from $50 at RBC Capital - TheFly
- 11 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial - TheFly
- 14 days ago - NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease - GlobeNewsWire
- 22 days ago - NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - GlobeNewsWire
- 4 weeks ago - NewAmsterdam Pharma Company Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - NewAmsterdam Pharma Company Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 5 weeks ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - GlobeNewsWire